Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study-Reference-Cited by-同舟云学术

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

Published:2008-05 Issue:5 Volume:9 Page:435-444
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Pfreundschuh Michael,Ho Anthony D,Cavallin-Stahl Eva,Wolf Max,Pettengell Ruth,Vasova Ingrid,Belch Andrew,Walewski Jan,Zinzani Pier-Luigi,Mingrone Walter,Kvaloy Stein,Shpilberg Ofer,Jaeger Ulrich,Hansen Mads,Corrado Claudia,Scheliga Adriana,Loeffler Markus,Kuhnt Evelyn

Publisher

Elsevier BV

Subject

Oncology

Reference47 articles.

1. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group;Pfreundschuh;Lancet Oncol,2006

2. A predictive model for aggressive non-Hodgkin's lymphoma;N Engl J Med,1993

3. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. Airlie House, Virginia, November 1997;Harris;J Clin Oncol,1999

4. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group;Cheson;J Clin Oncol,1999

5. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL;Pfreundschuh;Blood,2004

Cited by 188 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of initial tumor bulk in DLBCL treated with DA-EPOCH-R vs. R-CHOP: a secondary analysis of alliance/CALGB 50303;Leukemia & Lymphoma;2024-09-05

2. Metabolic tumour area: a novel prognostic indicator based on 18F-FDG PET/CT in patients with diffuse large B-cell lymphoma in the R-CHOP era;BMC Cancer;2024-07-25

3. Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume;Blood;2024-06-13

4. Radiotherapy in younger patients with advanced aggressive B-cell lymphoma—long-term results from the phase 3 R-MegaCHOEP trial;Leukemia;2024-03-27

5. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy;Cancer Medicine;2024-03